Cyclin D1 Expression and Patient Outcome after Tamoxifen Therapy in Estrogen Receptor Positive Brest Cancer .
10.4048/jkbcs.1999.2.2.221
- Author:
Sehwan HAN
1
;
Hong Yong KIM
;
Myung Soo LEE
;
Hong Joo KIM
;
Young Duck KIM
;
Kyeongmee PARK
;
Young Jin YUH
;
Sung Rok KIM
;
Hyun Suk SUH
Author Information
1. Department of Surgery, Inje University Sanggye Paik Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Differentiation;
Myc;
p27Kip1;
Prognosis;
Treatment
- MeSH:
Breast Neoplasms;
Cell Cycle;
Cell Differentiation;
Cyclin D1*;
Cyclins*;
Disease-Free Survival;
Estrogens*;
Humans;
Prognosis;
Tamoxifen*
- From:Journal of Korean Breast Cancer Society
1999;2(2):221-226
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Cyclin D1 expression is closely related with ER in breast cancer. We conducted this study to evaluate whether therapeutic response to tamoxifen is varied with levels of cyclin D1 expression in ER positive breast cancer patients. MATERIALS AND METHODS: Immunohistochemical assay for cyclin D1 protein was performed in 66 patients tasted with tamoxifen for more than 2years. Patient survival and correlation between cyclin D1 expression and biologic data of the patients were analyzed RESULTS: Cyclin D1 expression was detected in 46 (69.7%) and significantly reduced in poorly differentiated cancer (p=0.023). Cyclin D1 expression was high in the tumors expressing Myc (15/15 vs 31/51; p=0.002), and was markedly increased in the tumors in which p27Kip1 expression was repressed (30/38, 78.9%). However, the difference was not statistically significant (p=0.051). There was no significant relationship between cyclin D1 expression and S-phase. Patients with tumors expressing cyclinD1 showed better disease free survival and overall survival but the difference was not statistically significant. CONCLUSIONS: Cyclin D1 expression was associated with cell differentiation but not useful in discriminating high risk group with tamoxifem treatment. Cyclin D1 may have a role in process other than cell cycle regulator in ER positive breast cancer, such as differentiation signal.
